Baas F - Search Results

1

Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.

Mook OR, Baas F, de Wissel MB, Fluiter K. Mook OR, et al. Among authors: baas f. Mol Cancer Ther. 2007 Mar;6(3):833-43. doi: 10.1158/1535-7163.MCT-06-0195. Mol Cancer Ther. 2007. PMID: 17363479 Free article.

2

In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides.

Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F. Fluiter K, et al. Among authors: baas f. Nucleic Acids Res. 2003 Feb 1;31(3):953-62. doi: 10.1093/nar/gkg185. Nucleic Acids Res. 2003. PMID: 12560491 Free PMC article.

3

On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.

Fluiter K, Frieden M, Vreijling J, Rosenbohm C, De Wissel MB, Christensen SM, Koch T, Ørum H, Baas F. Fluiter K, et al. Among authors: baas f. Chembiochem. 2005 Jun;6(6):1104-9. doi: 10.1002/cbic.200400419. Chembiochem. 2005. PMID: 15861430

4

The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.

Fluiter K, Mook OR, Baas F. Fluiter K, et al. Among authors: baas f. Methods Mol Biol. 2009;487:189-203. doi: 10.1007/978-1-60327-547-7_9. Methods Mol Biol. 2009. PMID: 19301648 Review.

5

Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.

Fluiter K, Mook OR, Vreijling J, Langkjaer N, Højland T, Wengel J, Baas F. Fluiter K, et al. Among authors: baas f. Mol Biosyst. 2009 Aug;5(8):838-43. doi: 10.1039/b903922h. Epub 2009 May 19. Mol Biosyst. 2009. PMID: 19603119

6

Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A.

Mook OR, Baas F, de Wissel MB, Fluiter K. Mook OR, et al. Among authors: baas f. Cancer Gene Ther. 2009 Jun;16(6):532-8. doi: 10.1038/cgt.2008.104. Epub 2009 Jan 23. Cancer Gene Ther. 2009. PMID: 19165236

7

Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II.

Fluiter K, ten Asbroek AL, van Groenigen M, Nooij M, Aalders MC, Baas F. Fluiter K, et al. Among authors: baas f. Cancer Res. 2002 Apr 1;62(7):2024-8. Cancer Res. 2002. PMID: 11929820

8

Evaluation of LNA-modified DNAzymes targeting a single nucleotide polymorphism in the large subunit of RNA polymerase II.

Fluiter K, Frieden M, Vreijling J, Koch T, Baas F. Fluiter K, et al. Among authors: baas f. Oligonucleotides. 2005 Dec;15(4):246-54. doi: 10.1089/oli.2005.15.246. Oligonucleotides. 2005. PMID: 16396619

9

Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.

Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Baas F, Langklaer N, Wengel SL, Wengel J, Kjems J, Bramsen JB. Laursen MB, et al. Among authors: baas f. Mol Biosyst. 2010 May;6(5):862-70. doi: 10.1039/b918869j. Epub 2010 Feb 9. Mol Biosyst. 2010. PMID: 20567772

10

In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts.

Mook O, Vreijling J, Wengel SL, Wengel J, Zhou C, Chattopadhyaya J, Baas F, Fluiter K. Mook O, et al. Among authors: baas f. Artif DNA PNA XNA. 2010 Jul;1(1):36-44. doi: 10.4161/adna.1.1.12204. Artif DNA PNA XNA. 2010. PMID: 21687525 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

410 results

Search Page